Securities
and Exchange Commission
w
ashington,
D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of
|
May
|
|
2019
|
Commission File Number
|
001-36458
|
|
|
Neovasc
Inc.
|
(Translation of registrant’s name into English)
|
Suite 5138 - 13562 Maycrest Way
Richmond, British Columbia, Canada, V6V 2J7
|
(Address of principal executive offices)
|
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
DOCUMENTS INCLUDED AS PART OF THIS REPORT
Document
|
|
|
|
|
|
Document 1
|
|
News Release dated May 22, 2019 - Neovasc Announces Positive Two-Year Follow-up Safety and Efficacy Data for the Neovasc
Reducer™ in a Peer Reviewed Article in the International Journal of Cardiology
|
|
|
|
DOCUMENT 1
Neovasc Announces Positive Two-Year Follow-up
Safety and Efficacy Data for the Neovasc Reducer™ in a Peer Reviewed Article in the International Journal of Cardiology
NASDAQ, TSX: NVCN
VANCOUVER, May 22, 2019 /CNW/ - Neovasc Inc.
("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter
mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina,
today announced that the International Journal of Cardiology has published a peer reviewed article regarding long term sustained
efficacy and safety of the Reducer therapy in 50 patients suffering from refractory disabling angina. The title of the article
is: "Safety and efficacy of Coronary Sinus Reducer implantation at 2-year follow-up."
"This study shows us that the Reducer
has a sustained therapeutic effect at two years across a large patient population. In addition, we believe this study provides
valuable long-term safety data that further supports cardiologists use of the Reducer as a therapeutic option for patients suffering
from refractory angina," commented Prof. Shmuel Banai, Medical Director of Neovasc. "This data supports our belief that
the Reducer offers refractory angina patients a safe and effective treatment option, filling a void in a market where there are
currently limited therapeutic options."
The 50-patient study found that the Reducer
remains safe in the long-term with no device-related adverse events at the two year follow up. In addition, the reduction of angina
symptoms and the improvement of quality of life observed after Reducer therapy were maintained at 2-year follow-up.
About Reducer
The Reducer is CE-marked in the European Union for the treatment of refractory angina, a painful and debilitating condition that
occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization
or cardiac drug therapies. It affects millions of patients worldwide, who typically lead severely restricted lives as a result
of their disabling symptoms, and its incidence is growing. The Reducer provides relief of angina symptoms by altering blood flow
in the heart's circulatory system, thereby increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle.
Placement of the Reducer is performed using a minimally invasive transvenous procedure that is similar to implanting a coronary
stent and is completed in approximately 20 minutes.
While the Reducer is not approved for commercial
use in the USA, the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation to the Neovasc Reducer in October
2018. This designation is granted by the FDA in order to expedite the development and review of a device that demonstrates compelling
potential to provide a more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases.
In addition, there must be no FDA approved treatments presently available, or the technology must offer significant advantages
over existing approved alternatives.
Refractory angina, resulting in continued symptoms
despite maximal medical therapy and without revascularization options, is estimated to affect 600,000 to 1.8 million Americans,
with 50,000 to 100,000 new cases per year.
1
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular
marketplace. Its products include the Reducer, for the treatment of refractory angina, which is not currently commercially available
in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment
of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information,
visit: www.neovasc.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Forward-looking statements
may involve, but are not limited to, beliefs as to the study providing valuable long-term safety data that further supports cardiologists
use of the Reducer as a therapeutic option for patients suffering from refractory angina, beliefs that the Reducer offers refractory
angina patients a safe and effective treatment option, filling a void in a market where there are currently limited therapeutic
options and statements regarding the growing incidence of refractory angina and the growing cardiovascular marketplace. Many factors
and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed
or implied by the forward-looking statements, including, without limitation, the substantial doubt about the Company's ability
to continue as a going concern; risks relating to the Notes issued pursuant to the 2017 Financing, resulting in significant dilution
to the Company's shareholders; risks relating to the Company's need for significant additional future capital and the Company's
ability to raise additional funding; risks relating to cashless exercise and adjustment provisions in the Notes issued pursuant
to the 2017 Financing, which could make it more difficult and expensive for the Company to raise additional capital in the future
and result in further dilution to investors; risks relating to the sale of a significant number of common shares of the Company;
risks relating to the conversion of Notes issued pursuant to the 2017 Financing, which may encourage short sales by third parties;
risks relating to the possibility that the common shares of the Company may be delisted from the Nasdaq Capital Market or the Toronto
Stock Exchange, which could affect their market price and liquidity; risks relating to the Company's conclusion that it did not
have effective internal control over financial reporting as at December 31, 2018; risks relating to the Company's common share
price being volatile; risks relating to the influence of significant shareholders of the Company over the Company's business operations
and share price; risks relating to the Company's significant indebtedness, and its effect on the Company's financial condition;
risks relating to claims by third parties alleging infringement of their intellectual property rights; risks relating to lawsuits
that the Company is subject to, which could divert the Company's resources and result in the payment of significant damages and
other remedies; the Company's ability to establish, maintain and defend intellectual property rights in the Company's products;
risks relating to results from clinical trials of the Company's products, which may be unfavorable or perceived as unfavorable;
the Company's history of losses and significant accumulated deficit; risks associated with product liability claims, insurance
and recalls; risks relating to use of the Company's products in unapproved circumstances, which could expose the Company to liabilities;
risks relating to competition in the medical device industry, including the risk that one or more of the Company's competitors
may develop more effective or more affordable products; risks relating to the Company's ability to achieve or maintain expected
levels of market acceptance for the Company's products, as well as the Company's ability to successfully build its in-house sales
capabilities or secure third-party marketing or distribution partners; the Company's ability to convince public payors and hospitals
to include the Company's products on their approved products lists; risks relating to new legislation, new regulatory requirements
and the efforts of governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased
regulation, enforcement and inspections of participants in the medical device industry, including frequent government investigations
into marketing and other business practices; risks associated with the extensive regulation of the Company's products and trials
by governmental authorities, as well as the cost and time delays associated therewith; risks associated with post-market regulation
of the Company's products; health and safety risks associated with the Company's products and industry; risks associated with the
Company's manufacturing operations, including the regulation of the Company's manufacturing processes by governmental authorities
and the availability of two critical components of the Reducer; risk of animal disease associated with the use of the Company's
products; risks relating to the manufacturing capacity of third-party manufacturers for the Company's products, including risks
of supply interruptions impacting the Company's ability to manufacture its own products; risks relating to the Company's dependence
on limited products for substantially all of the Company's current revenues; risks relating to the Company's exposure to adverse
movements in foreign currency exchange rates; risks relating to the possibility that the Company could lose its foreign private
issuer status under U.S. federal securities laws; risks relating to breaches of anti-bribery laws by the Company's employees or
agents; risks associated with future changes in financial accounting standards and new accounting pronouncements; risks relating
to the Company's dependence upon key personnel to achieve its business objectives; the Company's ability to maintain strong relationships
with physicians; risks relating to the sufficiency of the Company's management systems and resources in periods of significant
growth; risks associated with consolidation in the health care industry, including the downward pressure on product pricing and
the growing need to be selected by larger customers in order to make sales to their members or participants; risks relating to
the Company's ability to successfully identify and complete corporate transactions on favorable terms or achieve anticipated synergies
relating to any acquisitions or alliances; risks relating to the Company's ability to successfully enter into fundamental transactions
as defined in the Notes issued pursuant to the 2017 Financings; anti-takeover provisions in the Company's constating documents
which could discourage a third party from making a takeover bid beneficial to the Company's shareholders; and risks relating to
conflicts of interests among the Company's officers and directors as a result of their involvement with other issuers. These risk
factors and others relating to the Company are discussed in greater detail in the "Risk Factors" section of the Company's
Annual Report on Form 20-F and in the Management's Discussion and Analysis for the three months ended March 31, 2019 (copies of
which may be obtained at www.sedar.com or www.sec.gov). The Company has no intention and undertakes no obligation to update or
revise any forward-looking statements beyond required periodic filings with securities regulators, whether as a result of new information,
future events or otherwise, except as required by law.
1
T. J. Povsic, S. Broderick, K. J. Anstrom et al., "Predictors of long
-
term clinical endpoints in patients with refractory angina," Journal of the American Heart Association, vol. 4, no. 2, article e001287, 2015.
|
View
original content:http://www.prnewswire.com/news-releases/neovasc-announces-positive-two-year-follow-up-safety-and-efficacy-data-for-the-neovasc-reducer-in-a-peer-reviewed-article-in-the-international-journal-of-cardiology-300855530.html
SOURCE Neovasc Inc.
View original content: http://www.newswire.ca/en/releases/archive/May2019/22/c7142.html
%CIK: 0001399708
For further information:
Chris Clark, Chief Financial Officer,
Neovasc Inc., 604 248-4138, cclark@neovasc.com; Jeremy Feffer, LifeSci Advisors, LLC, 212-915-2568, jeremy@lifesciadvisors.com
CO: Neovasc Inc.
CNW 17:30e 22-MAY-19
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Neovasc
Inc.
|
|
(Registrant)
|
Date:
|
|
May 22, 2019
|
|
By:
|
/s/
Chris Clark
|
|
Name: Chris Clark
Title: Chief
Financial Officer
|
|
|
|
|
|
|
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jul 2023 to Jul 2024